Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric carboxymaltose for perioperative anaemia
ACTRN12611000387921Phase 4Terminated
- Sponsor
- Lyell McEwin Hospital
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ferric carboxymaltose in anaemia (2 arms), sponsored by Lyell McEwin Hospital. Primary endpoint: Allogeneic transfusion rate. Started Aug 2011; status: terminated.
02
Drugs
ferric carboxymaltose
03
Conditions
anaemia
Beyond the preview
Go deeper on ACTRN12611000387921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000387921.